Aug 15 (Reuters) - National Australia Bank Ltd (NAB) :
- QTRLY CASH EARNINGS A$1.90 BILLION VERSUS A$1.80 BILLION REPORTED LAST YEAR
- QTRLY STATUTORY NET PROFIT A$1.75 BILLION VERSUS A$1.85 BILLION REPORTED YEAR AGO
- CET1 RATIO OF 11.9% AS AT QUARTER-END
- QTRLY NET INTEREST MARGIN 1.72%
- CONTINUE TO TARGET PRODUCTIVITY SAVINGS OF APPROXIMATELY A$400 MILLION IN FY23
- CREDIT IMPAIRMENT CHARGE OF A$244 MILLION FOR QUARTER
- COMPARED WITH MARCH 2023, RATIO OF COLLECTIVE PROVISIONS TO CREDIT RISK WEIGHTED ASSETS INCREASED BY 5 BPS TO 1.47% IN QUARTER
- RATIO OF 90+ DAYS PAST DUE AND GROSS IMPAIRED ASSETS TO GROSS LOANS AND ACCEPTANCES INCREASED 5 BPS TO 0.71% FOR QUARTER
- CAPITAL LEVELS REMAIN HEALTHY EVEN AFTER ALLOWING FOR LATEST ON-MARKET SHARE BUY-BACK ANNOUNCED TODAY
- LIQUIDITY AND COLLECTIVE PROVISION COVERAGE ARE STRONG AND WE RAISED A$37 BILLION OF TERM FUNDING BY END JULY
- Forums
- ASX - By Stock
- NAB
- News: NAB NAB Posts Quarterly Cash Earnings Of A$1.90 Billion
NAB
national australia bank limited
Add to My Watchlist
0.20%
!
$42.48

News: NAB NAB Posts Quarterly Cash Earnings Of A$1.90 Billion
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$42.48 |
Change
0.085(0.20%) |
Mkt cap ! $129.7B |
Open | High | Low | Value | Volume |
$42.10 | $42.54 | $42.09 | $131.9M | 3.247M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
28 | 2203 | $42.47 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$42.48 | 713 | 14 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
19 | 3902 | 42.460 |
14 | 4432 | 42.450 |
8 | 2585 | 42.440 |
11 | 2470 | 42.430 |
9 | 2225 | 42.420 |
Price($) | Vol. | No. |
---|---|---|
42.480 | 1684 | 14 |
42.490 | 1306 | 6 |
42.500 | 2940 | 14 |
42.510 | 2422 | 10 |
42.520 | 2490 | 9 |
Last trade - 13.34pm 22/08/2025 (20 minute delay) ? |
Featured News
NAB (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, MD & CEO
Michael Thurn
MD & CEO
SPONSORED BY The Market Online